摘要
他克莫司是一种新型强效免疫抑制剂,在临床广泛应用于肝移植等器官移植术后的抗排异治疗。在肝移植人群中,他克莫司的药代动力学及血药浓度存在个体差异,其用药的个体差异与细胞色素P450酶系CYP3A5和P糖蛋白的基因多态性之间存在较密切联系。本文对他克莫司的药效学、药代动力学、血药浓度范围及其药物基因组学的研究进展进行了综述。
Tacrolimus, a novel macrocyclic lactone with potent immunosuppressive properties, is generally used in organ transplantation to prevent allograft rejection. There is a wide interindividual variation in pharmacokinetics and therapeutic window of tacrolimus in liver transplant recipients. Recently, many studies indicated that there is a close association between interindividual variation of tacrolimus and genetic polymorphism of CYP3A5 and MDR1. In this review ,pharmacodynamics , pharmacokinetics , therapeutic window and pharmacogenomics of tacrolimus in liver transplantation are discussed.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2008年第2期165-168,共4页
The Chinese Journal of Clinical Pharmacology
关键词
他克莫司
肝移植
基因多态性
tacrolimus
liver transplantation
genetic polymorphism
作者简介
金昭（1978-），女，硕士研究生，药师，主要从事临床药理学研究
通讯作者：蔡卫民，主任药师，教授Tel：（021）64674478 E-mail：weimincai@hotmail．com
